Price to Operating Profit (P/OP)
since 2012
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Return on Assets (ROA) since 2012
- Debt to Equity since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
AbbVie Inc., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
- Share Price Trend
- The share price exhibits a general upward trend over the observed period, rising from $38.50 in March 2013 to $192.87 in February 2025. Notably, there are fluctuations within this period; a significant increase is seen between February 2017 and February 2018, where the price nearly doubled from $61.77 to $118.60. Following this peak, the share price experienced a decline, reaching $79.41 in February 2019, before recovering steadily to higher levels, culminating in the highest observed price of $192.87 in February 2025.
- Operating Profit per Share (OP) Behavior
- The operating profit per share shows variability throughout the period. It starts at $3.69 in March 2013, declines to a low of $2.14 in February 2015, but then rises sharply to a peak of $10.24 by February 2023. After this peak, a decreasing trend is observed, with OP falling to $7.22 in February 2024 and further declining to $5.18 in February 2025. This pattern indicates periods of both growth and contraction in operating profitability on a per-share basis.
- Price to Operating Profit (P/OP) Ratio Analysis
- The P/OP ratio, reflecting the share price relative to operating profit per share, shows significant volatility. Early in the period, the ratio ranges from 10.44 to 28.64, with the highest ratio occurring in February 2015, coinciding with a low OP value, indicating relatively high share price valuation against earnings. The ratio stabilizes somewhat in the following years, fluctuating around the mid-teens, before rising markedly again to 37.26 by February 2025. This last increase suggests that the share price growth is outpacing earnings growth, potentially indicating increased market expectations or reduced earnings relative to share price.
- Overall Financial Implications
- The data indicates a general increase in market valuation as reflected in share price appreciation, accompanied by fluctuations in operating profitability. The rising P/OP ratio in recent years may warrant closer monitoring as it suggests a divergence between market price and earnings performance, which could impact investor perception and valuation metrics in the future. The variability in operating profit per share highlights operational challenges and opportunities that have affected earnings consistently over the years.
Comparison to Competitors
AbbVie Inc., P/OP, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | |||||||
| Feb 20, 2024 | |||||||
| Feb 17, 2023 | |||||||
| Feb 18, 2022 | |||||||
| Feb 19, 2021 | |||||||
| Feb 21, 2020 | |||||||
| Feb 27, 2019 | |||||||
| Feb 16, 2018 | |||||||
| Feb 17, 2017 | |||||||
| Feb 19, 2016 | |||||||
| Feb 20, 2015 | |||||||
| Feb 21, 2014 | |||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).